Modulation of antigen delivery and lymph node activation in non-human primates by saponin adjuvant SMNP

• Published in: bioRxiv
• Main Authors: Yousefpour, Parisa, J Zhang, Yiming, Maiorino, Laura, Melo, Mariane B, Arainga Ramirez, Mariluz A, Kumarapperuma, Sidath C, Xiao, Peng, Silva, Murillo, Li, Na, Michaels, Katarzyna K, Georgeson, Erik, Eskandarzadeh, Saman, Kubitz, Michael, Groschel, Bettina, Qureshi, Kashif, Fontenot, Jane, Hangartner, Lars, Nedellec, Rebecca, Love, J Christopher, Burton, Dennis R, Schief, William R, Villinger, Francois J, Irvine, Darrell J
• Format: Journal Article
• Language: English
• Published: United States Cold Spring Harbor Laboratory 28.08.2024
• ISSN: 2692-8205; 2692-8205
• DOI: 10.1101/2024.08.28.608716

Saponin-based vaccine adjuvants are potent in preclinical animal models and humans, but their mechanisms of action remain poorly understood. Here, using a stabilized HIV envelope trimer immunogen, we carried out studies in non-human primates (NHPs) comparing the most common clinical adjuvant alum with Saponin/MPLA Nanoparticles (SMNP), a novel ISCOMs-like adjuvant. SMNP elicited substantially stronger humoral immune responses than alum, including 7-fold higher peak antigen-specific germinal center B cell responses, 18-fold higher autologous neutralizing antibody titers, and higher levels of antigen-specific plasma and memory B cells. PET-CT imaging in live NHPs showed that, unlike alum, SMNP promoted rapid antigen accumulation in both proximal and distal lymph nodes (LNs). SMNP also induced strong type I interferon transcriptional signatures, expansion of innate immune cells, and increased antigen presenting cell activation in LNs. These findings indicate that SMNP promotes multiple facets of the early immune response relevant for enhanced immunity to vaccination.